DWTX ▼ -7.2% - Dogwood Therapeutics, Inc. $DWTX - Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial Dogwood Therapeutics shares fell 7.2% today following the company's announcement that it has completed enrollment in its Phase 2b trial for Halneuron®. The market's negative reaction to the enrollment completion news suggests investors may have been expecting different trial metrics or timeline guidance, or may be factoring in the uncertainty inherent in the clinical trial process ahead of interim results. 14-SEP-2026 08:45 AM ET